This Biotech Just Made History. Will Its Stock Follow?
When then-President Bill Clinton announced the completion of the Human Genome Project in 2000, there was work left to do. The effort had really produced a "working draft" that would be completed three years later. It turns out even that announcement was a bit misleading. About 8% of our genetic instructions remained untouched even after the sequencing project officially ended.
According to researchers, those gaps have now been filled in. The accomplishment is thanks in large part to new sequencing technology from Pacific Biosciences of California (NASDAQ: PACB). PacBio's role in this technical achievement might not surprise anyone who has been following the company over the past year. Its most recent products opened up new possibilities in genomics. That could translate to huge gains for shareholders in the years ahead.
Image source: Getty Images.
Source Fool.com
